The expression of FGFR1 increased in BC cells with acquired resistance to ET and CDK4/6i, and combination of CDK4/6i with lucitanib or erdafitinib, a FGFR inhibitor, was sufficient to abrogate such resistance [162]. Here, CDK4 is linked to breast cancer.